Danimer Scientific — Q4 2023 Earnings Presentation
12 slides from Danimer Scientific's earnings presentation, Mar 28, 2024
Slide 1: Fourth Quarter 2023 Earnings Presentation
Fourth Quarter 2023 Earnings Presentation March 28, 2024
Slide 2: Disclaimer and Forward-Looking Statements
This presentation (“Presentation”) is for informational purposes only. This Presentation shall not constitute an offer to sell, or the solicitation of an offer to buy, any securities, nor shall there be any sale of securities in any states or jurisdictions in which such offer, solicitation or sale w
Slide 3: Fast Facts
FAST FACTS Founded in 2004 (went public in 2020) 480 patents & pending patent applications 15 partnerships with major brands and distributors 257 Teammates 2018 and 2020 recipient of PLASTICS Innovation in Bioplastics Award Locations in Georgia, Kentucky and New York Manufacturer and developer of PH
Slide 4: Commercial Updates and Customer Awards
Previously announced cutlery award expected to require ~20 million pounds of annual volume of Nodax® cutlery resins; first shipments anticipated mid-year 2024. Opportunities for the above cutlery award poised to expand into new geographical regions and additional end-product categories. Delta Cafés
Slide 5: Sales Cycle
Lead Evaluation Pre-Commercial Launch Material Selection Trials R&D / Product Development Certification Work Market Testing Regulatory Initial Sample New leads are screened by sales first, then a joint committee with R&D & sales if necessary; many do not make it past this stage 1 – 5 Years 6 Months
Slide 6: Sales Cycle (continued): Material Selection
Material Selection ~ 85 customers currently in “Material Selection” zone. Material selection zone is an iterative process, not necessarily a linear process. Sales Cycle (continued) Material Selection Trials R&D / Product Development Certification Work Market Testing Regulatory Initial Sample 6
Slide 7: Q4 and Full Year 2023 Financial Summary
Q4 and Full Year 2023 Financial Summary FY23 sales overall decreased compared to FY22 driven by higher PHA sales of $1.8M, which did not fully offset lower PLA sales of ($6.1M) due to the impact of the Ukraine conflict. Increased adjusted gross loss primarily reflects increased fixed costs associate
Slide 8: Fiscal 2024 Guidance Summary
Adjusted EBITDA guidance range of $(22) million to $(32) million. Capital expenditures guidance range of $8 million to $10 million. Ending cash balance for fiscal 2024 in the range of $20 million to $25 million. Guidance reflects anticipated timing of revenues associated with customer product launch
Slide 9: tess, ~ e
AN y . tess, ~ e Zé danimer \ oe soienutic. ‘y __ ABiotechnology Company
Slide 10: Adjusted EBITDA Reconciliation
Adjusted EBITDA Reconciliation 10
Slide 11: Adjusted Gross Profit Reconciliation
Adjusted Gross Profit Reconciliation 11
Slide 12: Thank You
a danimer ~ scientific THANK YOU